Hepatocyte growth factor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-11 and is reviewed periodically as new material appears.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
A physical or emotional change, occurring after a substance is taken or administered, that is not the result of any special property of the substance. The change may be beneficial, reflecting the expectations of the participant and, often, the expectations of the person giving the substance. (NLM) Placebo therapy
In October 2023, Galloway promoted the false claim that Volodymyr Zelenskyy's wife Olena Zelenska had spent $1 million on jewelry in New York City, during the time of which Zelenska was actually in Canada. Galloway said that his source for the story was The Nation, but the publication that had actually reported this claim was a Nigerian newspaper of the same name. Regarding the Crocus City Hall attack in Russia, Galloway said he had "four pieces of evidence that lead [him] to believe that the United States, its NATO allies, and their puppet stump state Ukraine are, in fact, responsible for this massacre". In October 2024, at the 16th BRICS summit, Galloway criticised the British press at the event for "hating Russia" and suggested there was more media freedom in Russia than in Britain. In June 2025, Galloway participated as a speaker at the Forum of the Future 2050 in Moscow, a conference organised by tycoon Konstantin Malofeev. The guest list also included Elon Musk's father, Errol Musk, Russia's foreign minister Sergey Lavrov, economist Jeffrey Sachs and conspiracy theorist Alex Jones, among others. After going into self-imposed exile in Russia, Galloway said on his talk show that he supports Russia's war against Ukraine, calling it anti-imperialist and anti-colonialist. He praised Russia's military after it struck Yahodyn, on the Polish border, with a drone.
In 2018, El Salvador cut diplomatic ties with Taiwan and recognized the People's Republic of China as China's legitimate government. This led to Bukele and the United States accusing China of interfering in Salvadoran and Latin American politics. Despite Bukele's criticism of China before becoming president, Vice President Félix Ulloa stated in May 2019 that Bukele's government would not restore diplomatic relations with Taiwan. In December 2019, Bukele met Chinese leader Xi Jinping in Beijing and signed a "gigantic" infrastructure agreement with China for an unknown amount of money. El Salvador and China have cooperated on infrastructure projects in El Salvador such as the National Library of El Salvador (completed in November 2023) and the National Stadium of El Salvador (construction began in November 2023). In November 2022, Bukele announced that El Salvador and China had begun negotiations for a free trade agreement between the countries. China donated fertilizer and wheat flour to El Salvador and, according to a Salvadoran government official, offered to buy El Salvador's external bond debt. Bukele stated that a free trade agreement with China was "very important" because El Salvador had been "isolated from [the] potential" of China's economic strength.
In City 17, Gordon Freeman and Alyx Vance (Merle Dandridge) have destroyed the Citadel's reactor. As it explodes, several vortigaunts (Louis Gossett Jr.) appear and extract Alyx. The G-Man (Michael Shapiro), who extracted Gordon from the explosion, is confronted by the vortigaunts and his psychic connection to Gordon is severed. Gordon awakens in the ruins of City 17, where he is rescued from a pile of rubble by Dog and reunited with Alyx. Alyx makes contact with Dr. Eli Vance (Robert Guillaume) and Dr. Isaac Kleiner (Harry S. Robins), who have escaped the city. Kleiner informs them that the Citadel's core will soon collapse and destroy the city. Gordon and Alyx proceed into the core to temporarily stabilize it. Alyx discovers that the Combine is attempting to accelerate its destruction to send a transmission back to their homeworld. She downloads a copy of the transmission and a video recorded by Judith Mossman (Michelle Forbes), in which she discusses the location of an unknown project before being subdued by a Combine attack. Gordon and Alyx board a Combine train to escape the Citadel, but it derails. They proceed underground and through the city streets, fighting past disorganized Combine forces and rampant Xen wildlife. Near a Combine-held train station, Gordon and Alyx reunite with Barney Calhoun (Michael Shapiro), to evacuate refugees from the city. They escort the refugees and take a different train out of City 17, escaping just as the reactor detonates, which delivers the Combine transmission.
The analysis done based on satellite measurement data, estimates δD for the air in various parts of the world. The general trend is that δD is more negative at higher latitude, so air above Antarctica and the Arctic is D-depleted to around −230‰ to −260‰ or even lower. The estimated atmospheric δDs are shown on the map. A vast portion of global atmospheric water vapor comes from the Western Pacific near the tropics, (mean 2009) and the HIC of air depends on temperature and humidity. Hot, humid regions generally have higher δD. Water vapor in the air is in general more depleted than terrestrial water sources, since 1H216O evaporates faster than 1H2H16O due to higher vapor pressure. On the other hand, rain water is in general more enriched than atmospheric water vapor.
Sources: en.wikipedia.org
==== Omicron variant ==== During the emergence of the Omicron variant of COVID-19 in December 2021 and January 2022, Ford's government announced in December 2021 new restrictions on indoor settings. After growing calls for third or booster doses of COVID-19 vaccines, the government allowed all Ontarians over 18 years of age to receive a third dose on December 20, 2021. On January 3, 2022, Ford announced that Ontario would be moving into modified Step 2 on January 5, closing indoor dining, gyms, movie theatres and schools.
GeneDx is an American biotechnology company specializing in genomic diagnostics, with a focus on whole genome sequencing (WGS) and whole exome sequencing (WES) for the diagnosis of rare and inherited disorders. The company provides genetic testing services to healthcare providers, hospitals, and health systems, and contributes to advancements in genomic medicine through research, biopharma partnerships, and advocacy. The company is headquartered in Stamford, Connecticut, with its clinical laboratory in Gaithersburg, Maryland, and is publicly traded on the Nasdaq under the ticker symbol WGS. GeneDx was founded in 2000 by Sherri Bale and John Compton, scientists from the National Institutes of Health (NIH), to provide diagnostic services for patients with rare and ultra-rare disorders. The company was acquired by BioReference Laboratories in 2006 and subsequently by Sema4 in 2022, after which it underwent a strategic transformation refocusing on whole exome and genome sequencing in pediatrics and changed its name to GeneDx. Since launching exome testing in 2011, the company has built GeneDx Infinity, a large and diverse rare disease dataset including more than one million clinically sequenced exomes and genomes, more than 2.5 million tests, and more than 8 million phenotypic datapoints. In 2024, GeneDx reported revenue of $302.3 million, representing 56% year-over-year growth, and announced its first profitable quarter. For full-year 2025, the company reported revenue of approximately $427 million.
DCC (acronym for N,N'-dicyclohexylcarbodiimide) was one of the first carbodiimides developed as a reagent. It is widely used for amide and ester formation, especially for solid-phase synthesis of peptides. DCC has achieved popularity mainly because of its high-yielding amide coupling reactions and the fact that it is quite inexpensive. However, DCC does have some serious drawbacks, and its use is often avoided for several reasons:
Opium has been actively collected since approximately 3400 BC. Ancient alabaster residue reveals deliberate opium use in Egypt, suggesting royal tombs may have contained valuable narcotics prized by pharaohs. At least 17 finds of Papaver somniferum from Neolithic settlements have been reported throughout Switzerland, Germany, and Spain, including the placement of large numbers of poppy seed capsules at a burial site (the Cueva de los Murciélagos, or "Bat Cave", in Spain), which has been carbon-14 dated to 4200 BC. Numerous finds of P. somniferum or P. setigerum from Bronze Age and Iron Age settlements have also been reported. The first known cultivation of opium poppies was in Mesopotamia, approximately 3400 BCE, by Sumerians, who called the plant hul gil, the "joy plant". Tablets found at Nippur, a Sumerian spiritual center south of Baghdad, described the collection of poppy juice in the morning and its use in production of opium. Cultivation continued in the Middle East by the Assyrians, who also collected poppy juice in the morning after scoring the pods with an iron scoop; they called the juice aratpa-pal, possibly the root of Papaver. Opium production continued under the Babylonians and Egyptians. Opium was used with poison hemlock to put people quickly and painlessly to death. It was also used in medicine. Spongia somnifera, sponges soaked in opium, were used during surgery. The Egyptians cultivated opium thebaicum in famous poppy fields around 1300 BC.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.